Global Proliferative Diabetic Retinopathy Market – Industry Trends and Forecast to 2029

Global Proliferative Diabetic Retinopathy Market, By (Drug Class - Anti-VEGF Agents, and Corticosteroids), Mode of Administration (Injectables, Oral, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)– Industry Trends and Forecast to 2029

Proliferative Diabetic Retinopathy Market Analysis and Size

According to the Centers for Disease Control and Prevention, 655,000 persons with diabetic retinopathy and approximately 4.2 million adults overall have the condition. Additionally, rising healthcare costs and a solid healthcare infrastructure significantly boost the growth of the regional market as a whole.

Data Bridge Market Research analyses that the proliferative diabetic retinopathy market which was USD 1969.07 million in 2021, would rocket up to USD 3617.70 million by 2029, and is expected to undergo a CAGR of 7.90% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Market Definition

Proliferative diabetic retinopathy is a consequence of diabetes brought on by alterations in the blood vessels of the eyes. If left untreated, this condition can result in additional serious eye conditions and long-term vision loss. The most severe form of diabetic retinopathy, proliferative diabetic retinopathy, is characterised by the development of new blood vessels on the retina's surface.

Proliferative Diabetic Retinopathy Market Dynamics

Drivers

• Rise in demand of angiogenesis

Angiogenesis will play a significant role in the aetiology of proliferative diabetic retinopathy, and intravitreal antiangiogenic injection has been proposed as a potential treatment for the condition. Proliferative diabetic retinopathy is being effectively treated using a variety of antiangiogenic strategies, which will likely play crucial roles in the treatment and prevention of the condition in the next years.

• Rise in disposable income

Consumers' increasing disposable income and worries about vision loss have had an impact on how much money patients are willing to spend on the essential therapy for diabetic retinopathy. Patients with proliferative diabetic retinopathy may be more inclined to choose surgical therapies if there is access to cutting-edge technology and minimally invasive laser therapy that also offers quicker recovery.

Opportunities

Globally, the geriatric population has been growing significantly, and this population segment is particularly vulnerable to many chronic diseases including diabetes. Therefore, older people are more likely to acquire proliferative diabetic retinopathy. This has increased the need for efficient medications to treat proliferative diabetic retinopathy in the elderly population.

Restraints/Challenges

• Strignent guidelines

The pandemic has fundamentally altered how many industries and enterprises are growing. The supply chain systems have been severely hampered by the border restrictions and the rigorous stay-at-home orders. Thus, all these aspects have negatively influenced the growth of the proliferative diabetic retinopathy market. 

This proliferative diabetic retinopathy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the proliferative diabetic retinopathy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Proliferative Diabetic Retinopathy Market

The global market for proliferative diabetic retinopathy is expected to suffer as a result of the COVID-19 epidemic. Globally, the COVID-19 outbreak has impacted healthcare industry workflows. As ophthalmological care is heavily dependent on specialised imaging equipment that is not readily available outside of ophthalmologists' offices, which is impeding market growth. Ophthalmic outpatient visits were largely reduced to urgent and emergent cases only, and the procedures and operations were postponed.

Global Proliferative Diabetic Retinopathy Market Scope

The proliferative diabetic retinopathy market is segmented on the basis of type, mode of administration and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

????

• ?nt?-V?GF ?g?nt?
• ??rt????t?r??d?

Mode of Administration

• Injectables
• Oral
• Others

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Proliferative Diabetic Retinopathy Market Regional Analysis/Insights

The proliferative diabetic retinopathy market is analysed and market size insights and trends are provided by country, type, mode of administration and distribution channel as referenced above.

The countries covered in the proliferative diabetic retinopathy market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to dominate the market due to growing prevalence of diabetes and diabetic retinopathy.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to the growing health awareness among the people.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Proliferative Diabetic Retinopathy Market Share Analysis

The proliferative diabetic retinopathy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to proliferative diabetic retinopathy market.

Some of the major players operating in the proliferative diabetic retinopathy market are:

• ?nt?? ?h?rm???ut???l? Ltd. (India)
• N?v?rt?? AG (Switzerland)
• ?f?z?r Inc. (U.S.)
• Kowa Company, Ltd. (Japan)
• Sirnaomics (U.S.)
• Glycadia Pharmaceuticals (U.S.)
• BCN Peptides (Spain)
• Santen Pharmaceutical Co., Ltd. (Japan)
• Alimera Sciences (U.S.)
• Ampio Pharmaceuticals Inc. (U.S.)
• ThromboGenics NV (Belgium)
• Bayer AG (Germany)